



## Letter to the Editor

## Inactivation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by gaseous ozone treatment



Sir,

Infection with severe acute respiratory coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, has become a worldwide pandemic [1]. The symptoms of COVID-19 vary widely from asymptomatic disease to pneumonia, and COVID-19 is capable of causing life-threatening complications such as acute respiratory distress syndrome, multisystem organ failure, and ultimately death. Older patients and those with pre-existing respiratory or cardiovascular conditions appear to be at the greatest risk for severe complications.

Ozone gas is effective against the majority of microorganisms tested by numerous research groups, and relatively low concentrations of ozone and short contact time are sufficient to inactivate bacteria, fungus, parasites, and viruses [2–5]. Because of this, ozone should be considered for adoption as an effective weapon in the global fight against COVID-19. In this study, we evaluated the efficacy of ozone gas for inactivation of SARS-CoV-2.

We used the SARS-CoV-2 (JPN/TY/WK-521) strain, which was isolated and provided by the National Institute of Infectious Diseases, Japan. The SARS-CoV-2 culture was performed using VeroE6/TMPRSS2 cells (JCRB1819). Virus culture broths were harvested by two cycles of freezing and thawing and clarified by centrifugation at 10,000 g for 15 min at 4°C. We subjected the supernatant to ultrafiltration (Amicon Ultra-15; Merck Millipore Ltd., IRL), followed by three washing steps with phosphate-buffered saline. A sample (50 µL;  $8.5 \times 10^5$  pfu) of viral suspension was deposited on a 3-cm<sup>2</sup> area of stainless-steel plates. The plates were allowed to dry before exposure to ozone gas and were exposed to ozone immediately after drying. The plates were placed in an ozone-proof airtight acrylic box (height: 23 cm, depth: 30 cm, width: 40 cm) with the device generating ozone gas (TM-040Z; Tamura TECO Ltd., Japan) and were 15 cm away from the device. The plates were then exposed at a concentration of 1.0 ppm ozone for 60 min (Concentration-Time (CT) Value 60) and 6.0 ppm of ozone at 55 min (CT value 330) at temperature 25°C and relative humidity of 60–80%. In each experiment, plates placed for 60 or 55 min without ozone exposure were used as controls. Each plate was

placed in a 50-mL tube containing 5 mL Dulbecco's modified Eagle's medium D-MEM (FUJIFILM Wako Pure Chemical Corporation, Japan), and the solution containing a plate was mixed for 1 min on a vortex mixer to dislodge any attached virus. The virus titre of SARS-CoV-2 was determined by using the plaque technique on confluent layers of VeroE6/TMPRSS2 cell cultures grown in 12-well culture plates as described previously [6]. This study was conducted in a BSL-3 laboratory at Nara Medical University.

The plaque assay before exposure of ozone was  $1.7 \times 10^7$  pfu/mL. The titre after exposure of 1.0 ppm ozone at 60 min was  $1.7 \times 10^4$  compared with  $5.8 \times 10^5$  pfu/mL for the control. After exposure to 6.0 ppm ozone at 55 min, the titre was less than or equal to  $1.0 \times 10^3$  pfu/mL, compared with  $2.0 \times 10^6$  pfu/mL for the control. The titre decreased significantly following exposure to ozone, suggesting that ozone inactivated SARS-CoV-2.

Studies of disinfection with surrogate viruses used ozone concentrations in the range of 10–20 ppm for shorter periods [2,3]. Using higher ozone concentrations for shorter periods may make the process more logistically feasible in busy hospitals where short room turnaround times are required. However, as it is acknowledged that high concentrations can damage equipment and items, the use of lower concentrations may be desirable in some situations. The low-concentration device we used would be better suited for use at night when there are no patients.

The transmission routes of SARS-CoV-2 include droplet transmission, including cough, sneeze, and droplet inhalation transmission. In addition, SARS-CoV-2 may spread by contact transmission and be acquired in numerous indoor public spaces, including hospitals. The surface environment in patient's room may be frequently contaminated [7,8], and contact with these contaminated surfaces may result in hand contamination of healthcare personnel that may be transferred to patients. Therefore, there is a need to develop methods of disinfection. Ozone gas can reach every corner of the environment, including sites that might prove difficult to gain access to with conventional liquids and manual cleaning procedures. In addition, ozone gas is very easy to manufacture as it is produced by electrolysis and does not require replenishment of raw materials.

Recently, Blanchard *et al.* reported ozone-disinfected influenza A virus and respiratory syncytial virus that would serve as a reasonable surrogate for SARS-CoV-2 [2]. These results suggested that ozone has an effect on SARS-CoV-2, as we have demonstrated in this study. To our knowledge, this is the first report about the inactivation of SARS-CoV-2 by ozone,

and our findings suggest that ozone could be added to the disinfection options for use in the future.

#### Conflict of interest statement

None declared.

#### Funding sources

None.

#### References

- [1] Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. *Acta Biomed* 2020;91:157–60.
- [2] Blanchard EL, Lawrence JD, Noble JA, Xu M, Joo T, Ng NL, et al. Enveloped virus inactivation on personal protective equipment by exposure to ozone. *medRxiv* 2020;2020. <https://doi.org/10.1101/2020.05.23.20111435>.
- [3] Hudson JB, Sharma M, Petric M. Inactivation of Norovirus by ozone gas in conditions relevant to healthcare. *J Hosp Infect* 2007;66:40–5.
- [4] Sharma M, Hudson JB. Ozone gas is an effective and practical antibacterial agent. *Am J Infect Control* 2008;36:559–63.
- [5] Moore G, Griffith C, Peters A. Bactericidal properties of ozone and its potential application as a terminal disinfectant. *J Food Prot* 2000;63:1100–6.
- [6] Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qin Hai M, Yongxia S, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). *Pharmacol Res* 2020;156:104761.
- [7] Hardy KJ, Oppenheim BA, Gossain S, Gao F, Hawkey PM. A study of the relationship between environmental contamination with methicillin-resistant *Staphylococcus aureus* (MRSA) and patients' acquisition of MRSA. *Infect Control Hosp Epidemiol* 2006;27:127–32.
- [8] Muzslay M, Moore G, Turton JF, Wilson AP. Dissemination of antibiotic-resistant enterococci within the ward environment: the role of airborne bacteria and the risk posed by unrecognized carriers. *Am J Infect Control* 2013;41:57–60.

H. Yano<sup>a</sup>  
 R. Nakano<sup>a,\*</sup>  
 Y. Suzuki<sup>a</sup>  
 A. Nakano<sup>a</sup>  
 K. Kasahara<sup>b</sup>  
 H. Hosoi<sup>c</sup>

<sup>a</sup>Department of Microbiology and Infectious Diseases, Nara Medical University, Nara, Japan

<sup>b</sup>Center for Infectious Diseases, Nara Medical University, Nara, Japan

<sup>c</sup>MBT (Medicine-Based Town) Institute, Nara Medical University, Nara, Japan

\* Corresponding author. Department of Microbiology and Infectious Diseases, Nara Medical University, Shijo-cho, Kashihara, Nara, 634-8521. Japan.  
 E-mail address: [rnakano@naramed-u.ac.jp](mailto:rnakano@naramed-u.ac.jp) (R. Nakano)

Available online 10 October 2020